Follow on Google News News By Tag * Surefire Medical * Liver Cancer * Radioembolization * Chemoembolization * Surefire Infusion System * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Best Hospitals, Best Cancer Centers Rapidly Adopt Surefire Infusion SystemGrowing body of clinical evidence shows greater tumor penetration, targeted delivery, efficiency and cost savings with the Surefire device
By: Surefire Medical “First, I find it to be effective in preventing reflux,” says Dr. Eric Reiner, Associate Professor of Diagnostic Radiology at the Yale School of Medicine and an Interventional Radiologist at Yale-New Haven Hospital, a best cancer hospital. “Just as important, I find it to be really excellent in improving tumor uptake of the embolic agents in Drug Eluting Bead (DEB) and Transarterial Chemo Embolization (TACE) procedures.” Liver cancer is the third most common cause of cancer deaths worldwide, with 2.2 million cases. In the U.S. liver cancer deaths doubled between 1981 and 2010, from eight to 16.3 deaths per 100,000, according to the Centers for Disease Control and Prevention (CDC). The growing preference for the novel Surefire Infusion System with its telescoping tip reflects results of a growing body of published data showing evidence of: · Far greater penetration of dose into tumors · A 70 percent reduction in fluoroscopy exposure · Up to 50 percent reduction in procedure time. “That the nation’s top-rated hospitals have so quickly come to prefer the performance of the Surefire Infusion System clearly substantiates our device’s growing market leadership in interventional procedures,” About Surefire Medical Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|